Application of metabolomics in thyroid cancer research

International Journal of Endocrinology

Volumn 2015, Issue , 2015, Pages

  Wojakowska, Anna ^a   Chekan, Mykola ^a   Widlak, Piotr ^a   Pietrowska, Monika ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACYL COENZYME A DESATURASE 1; BIOLOGICAL MARKER; CARNITINE; FATTY ACID SYNTHASE; LIPIDOME; PHOSPHATIDIC ACID; PHOSPHATIDYLCHOLINE; SPHINGOMYELIN;

AMINO ACID METABOLISM; CANCER CLASSIFICATION; CANCER GROWTH; CANCER STAGING; CITRIC ACID CYCLE; DIAGNOSTIC VALUE; DNA FINGERPRINTING; DNA MICROARRAY; GENE EXPRESSION; HIGH RESOLUTION MAGIC ANGLE SPINNING NUCLEAR MAGNETIC RESONANCE; HUMAN; LIPID METABOLISM; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE; OSMOREGULATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; THYROID CANCER;

EID: 84929378531     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2015/258763     Document Type: Review

References (134)

1. W. C. Faquin, "The thyroid gland: recurring problems in histologic and cytologic evaluation, " Archives of Pathology and Laboratory Medicine, vol. 132, no. 4, pp. 622-632, 2008.
2. M. Xing, B. R. Haugen, and M. Schlumberger, "Progress in molecular-based management of differentiated thyroid cancer, " The Lancet, vol. 381, no. 9871, pp. 1058-1069, 2013.
3. O. Koperek, C. Kornauth, D. Capper et al. , "Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma, "The American Journal of Surgical Pathology, vol. 36, no. 6, pp. 844-850, 2012.
4. J. Zagzag, A. Pollack, L. Dultz et al. , "Clinical utility of immunohistochemistry for the detection of the BRAF v600emutation in papillary thyroid carcinoma, " Surgery, vol. 154, no. 6, pp. 1199-1205, 2013.
5. A. Greco, M. G. Borrello, C. Miranda, D. Degl'Innocenti, and M. A. Pieroiti, "Molecular pathology of differentiated thyroid cancer, " Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 53, no. 5, pp. 440-454, 2009.
6. W. Weckwerth, "Metabolomics in systems biology, " Annual Review of Plant Biology, vol. 54, pp. 669-689, 2003.
7. R. D. Beger, "A review of applications of metabolomics in cancer, " Metabolites, vol. 3, no. 3, pp. 552-574, 2013.
8. J. L. Griffin and J. P. Shockcor, "Metabolic profiles of cancer cells, " Nature Reviews Cancer, vol. 4, no. 7, pp. 551-561, 2004.
9. J. L. Spratlin, N. J. Serkova, and S. G. Eckhardt, "Clinical applications of metabolomics in oncology: a review, " Clinical Cancer Research, vol. 15, no. 2, pp. 431-440, 2009.
10. F. A. Howe, S. J. Barton, S. A. Cudlip et al. , "Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy, " Magnetic Resonance in Medicine, vol. 49, no. 2, pp. 223-232, 2003.
11. C. Denkert, E. Bucher, M. Hilvo et al. , "Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery, " Genome Medicine, vol. 4, no. 4, article 37, 2012.
12. T. Kind, V. Tolstikov, O. Fiehn, and R. H. Weiss, "A comprehensive urinary metabolomic approach for identifying kidney cancerr, " Analytical Biochemistry, vol. 363, no. 2, pp. 185-195, 2007.
13. E. Thysell, I. Surowiec, E. Hrnberg et al. , "Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol, " PLoS ONE, vol. 5, no. 12, Article ID e14175, 2010.
14. M. J. Welker and D. Orlov, "Thyroid nodules, " American Family Physician, vol. 67, no. 3, pp. 559-573, 2003.
15. E. S. Cibas and S. Z. Ali, "The Bethesda system for reporting thyroid cytopathology, " American Journal of Clinical Pathology, vol. 132, no. 5, pp. 658-665, 2009.
16. P. Mehra and A. K. Verma, "Thyroid cytopathology reporting by the bethesda system: a two-year prospective study in an academic institution, " Pathology Research International, vol. 2015, Article ID 240505, 11 pages, 2015.
17. T. Kim, Y. L. Oh, K. M. Kim, and J. H. Shin, "Diagnostic dilemmas of hyalinizing trabecular tumours on fine needle aspiration cytology: a study of seven cases with BRAFmutation analysis, " Cytopathology, vol. 22, no. 6, pp. 407-413, 2011.
18. E. Bakua-Zalewska, R. Cameron, J. P. Gaczyski, and H. A. Domanski, "Hyaline matrix in hyalinizing trabecular tumor: findings in fine-needle aspiration smears, " Diagnostic Cytopathology, 2014.
19. B. Ustun, D. Chhieng, M. L. Prasad et al. , "Follicular variant of papillary thyroid carcinoma: accuracy of FNA diagnosis and implications for patient management, " Endocrine Pathology, vol. 25, pp. 257-264, 2014.
20. L. Jin, T. J. Sebo, N. Nakamura et al. , "BRAFmutation analysis in fine needle aspiration (FNA) cytology of the thyroid, " Diagnostic Molecular Pathology, vol. 15, no. 3, pp. 136-143, 2006.
21. S. J. Johnson, S. A. Hardy, C. Roberts, D. Bourn, U. Mallick, and P. Perros, "Pilot of BRAF mutation analysis in indeterminate, suspicious and malignant thyroid FNA cytology, " Cytopathology, vol. 25, no. 3, pp. 146-154, 2014.
22. S. P. Hodak and D. S. Rosenthal, "Information for clinicians: commercially available molecular diagnosis testing in the evaluation of thyroid nodule fine-needle aspiration specimens, " Thyroid, vol. 23, no. 2, pp. 131-134, 2013.
23. J. F. Krane, "Lessons from early clinical experience with the Afirma gene expression classifier, " Cancer Cytopathology, vol. 122, no. 10, pp. 715-719, 2014.
24. M. Papotti, J. Rodriguez, R. de Pompa, A. Bartolazzi, and J. Rosai, "Galectin-3 and HBME-1 expression in welldifferentiated thyroid tumors with follicular architecture of uncertain malignant potential, " Modern Pathology, vol. 18, no. 4, pp. 541-546, 2005.
25. O. L. Griffith, C. G. Chiu, A. M. Gown, S. J. M. Jones, and S. M. Wiseman, "Biomarker panel diagnosis of thyroid cancer: a critical review, " Expert Review of AnticancerTherapy, vol. 8, no. 9, pp. 1399-1413, 2008.
26. D. El Demellawy, A. L. Nasr, S. Babay, and S. Alowami, "Diagnostic utility ofCD56 immunohistochemistry in papillary carcinoma of the thyroid, " Pathology-Research and Practice, vol. 205, no. 5, pp. 303-309, 2009.
27. M. Mokhtari, M. Eftekhari, and R. Tahririan, "Absent CD56 expression in papillary thyroid carcinoma: a finding of potential diagnostic value in problematic cases of thyroid pathology, " Journal of Research inMedical Sciences, vol. 18, no. 12, pp. 1046-1050, 2013.
28. K. Shahebrahimi, S. H. Madani, A. Fazaeli, S. Khazaei, M. Kanani, and A. Keshavarz, "Diagnostic value of CD56 and nm23 markers in papillary thyroid carcinoma, " Indian Journal of Pathology & Microbiology, vol. 56, no. 1, pp. 2-5, 2013.
29. C. Hedinger, E. D. Williams, and L. H. Sobin, "Histological typing of thyroid tumors, " in International Histological Classification of Tumours, vol. 11, Springer, Berlin, Germany, 2nd edition, 1988.
30. S. L. Wood, J. A. Westbrook, and J. E. Brown, "Omic-profiling in breast cancer metastasis to bone: Implications for mechanisms, biomarkers and treatment, " Cancer Treatment Reviews, vol. 40, no. 1, pp. 139-152, 2014.
31. C. M. Perou, T. Sile, M. B. Eisen et al. , "Molecular portraits of human breast tumours, " Nature, vol. 406, no. 6797, pp. 747-752, 2000.
32. A. MacKay, B. Weigelt, A. Grigoriadis et al. , "Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement, " Journal of the National Cancer Institute, vol. 103, no. 8, pp. 662-673, 2011.
33. Y. Su, Y. Zheng, W. Zheng et al. , "Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study, " BMC Cancer, vol. 11, article 292, 2011.
34. K.-J. Kao, K.-M. Chang, H.-C. Hsu, and A. T. Huang, "Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization, " BMC Cancer, vol. 11, article 143, 2011.
35. Y. Huang, M. Prasad, W. J. Lemon et al. , "Gene expression in papillary thyroid carcinoma reveals highly consistent profiles, " Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 26, pp. 15044-15049, 2001.
36. T. J. Giordano, R. Kuick, D. G. Thomas et al. , "Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis, " Oncogene, vol. 24, no. 44, pp. 6646-6656, 2005.
37. M. A. Aldred, Y. Huang, S. Liyanarachchi et al. , "Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes, " Journal of Clinical Oncology, vol. 22, no. 17, pp. 3531-3539, 2004.
38. B. Jarza, M. Wiench, K. Fujarewicz et al. , "Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications, " Cancer Research, vol. 65, no. 4, pp. 1587-1597, 2005.
39. K. Fujarewicz, M. Jarza, M. Eszlinger et al. , "A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping, " Endocrine-RelatedCancer, vol. 14, no. 3, pp. 809-826, 2007.
40. M. Eszlinger, K. Krohn, A. Kukulska, B. Jarza, and R. Paschke, "Perspectives and limitations of microarray-based gene expression profiling of thyroid tumors, " Endocrine Reviews, vol. 28, no. 3, pp. 322-338, 2007.
41. B. L. Hood, N. A. S. Stewart, and T. P. Conrads, "Development of high-throughput mass spectrometry-based approaches for cancer biomarker discovery and implementation, " Clinics in Laboratory Medicine, vol. 29, no. 1, pp. 115-138, 2009.
42. C. Fredolini, L. A. Liotta, and E. F. Petricoin, "Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy, " Critical Reviews in Clinical Laboratory Sciences, vol. 47, no. 3, pp. 125-138, 2010.
43. M. deWit, R. J. A. Fijneman, H. M. W. Verheul, G. A. Meijer, and C. R. Jimenez, "Proteomics in colorectal cancer translational research: biomarker discovery for clinical applications, " Clinical Biochemistry, vol. 46, no. 6, pp. 466-479, 2013.
44. P. Alvarez-Chaver, O. Otero-Estvez, M. P. de la Cadena, F. J. Rodruez-Berrocal, and V. S. Martez-Zorzano, "Proteomics for discovery of candidate colorectal cancer biomarkers, " World Journal of Gastroenterology, vol. 20, no. 14, pp. 3804-3824, 2014.
45. S. S. Schneider, R. Aslebagh, A. G. Wetie, S. R. Sturgeon, C. C. Darie, and K. F. Arcaro, "Using breast milk to assess breast cancer risk: the role of mass spectrometry-based proteomics, " Advances in Experimental Medicine and Biology, vol. 806, pp. 399-408, 2014.
46. K. Krause, B. Jeitzer, and D. Fuhrer, "Proteomics in thyroid tumor research, " Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 8, pp. 2717-2724, 2009.
47. L. M. Brown, S. M. Helmke, S. W. Hunsucker et al. , "Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue, " Molecular Carcinogenesis, vol. 45, no. 8, pp. 613-626, 2006.
48. R. T. Netea-Maier, S. W. Hunsucker, B. M. Hoevenaars et al. , "Discovery and validation of protein abundance differences between follicular thyroid neoplasms, " Cancer Research, vol. 68, no. 5, pp. 1572-1580, 2008.
49. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation, " Cell, vol. 144, no. 5, pp. 646-674, 2011.
50. A. M. Weljie and F. R. Jirik, "Hypoxia-induced metabolic shifts in cancer cells: moving beyond the Warburg effect, " International Journal of Biochemistry and Cell Biology, vol. 43, no. 7, pp. 981-989, 2011.
51. M. G. V. Heiden, L. C. Cantley, and C. B. Thompson, "Understanding the warburg effect: the metabolic requirements of cell proliferation, " Science, vol. 324, no. 5930, pp. 1029-1033, 2009.
52. O. Warburg, "On the origin of cancer cells, " Science, vol. 123, no. 3191, pp. 309-314, 1956.
53. B. Sitter, U. Sonnewald, M. Spraul, H. E. Fjsne, and I. S. Gribbestad, "High-resolution magic angle spinning MRS of breast cancer tissue, "NMR in Biomedicine, vol. 15, no. 5, pp. 327-337, 2002.
54. M. G. Swanson, A. S. Zektzer, Z. L. Tabatabai et al. , "Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy, " Magnetic Resonance in Medicine, vol. 55, no. 6, pp. 1257-1264, 2006.
55. P. Miccoli, L. Torregrossa, L. Shintu et al. , "Metabolomics approach to thyroid nodules: a high-resolution magic-angle spinning nuclear magnetic resonance-based study, " Surgery, vol. 152, no. 6, pp. 1118-1124, 2012.
56. J. A. Menendez and R. Lupu, "Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis, " Nature Reviews Cancer, vol. 7, no. 10, pp. 763-777, 2007.
57. M. Hilvo, C. Denkert, L. Lehtinen et al. , "Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression, " Cancer Research, vol. 71, no. 9, pp. 3236-3245, 2011.
58. S. Guo, L. Qiu, Y. Wang et al. , "Tissue imaging and serum lipidomic profiling for screening potential biomarkers of thyroid tumors by matrix-assisted laser desorption/ionization-Fourier transformion cyclotron resonancemass spectrometry, " Analytical and Bioanalytical Chemistry, vol. 406, no. 18, pp. 4357-4370, 2014.
59. R. A. Cairns, I. S. Harris, and T. W. Mak, "Regulation of cancer cell metabolism, " Nature Reviews Cancer, vol. 11, no. 2, pp. 85-95, 2011.
60. C. M. Metallo, P. A. Gameiro, E. L. Bell et al. , "Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia, " Nature, vol. 481, no. 7381, pp. 380-384, 2012.
61. K. Glunde, Z. M. Bhujwalla, and S. M. Ronen, "Choline metabolism in malignant transformation, " Nature Reviews Cancer, vol. 11, no. 12, pp. 835-848, 2011.
62. W. R. Bishop and R. M. Bell, "Assembly of phospholipids into cellular membranes: biosynthesis, transmembrane movement and intracellular translocation, " Annual Review of Cell Biology, vol. 4, pp. 579-610, 1988.
63. M. L. Dria, Z. Cotrim, B. MacEdo et al. , "Lipidomic approach to identify patterns in phospholipid profiles and define class differences in mammary epithelial and breast cancer cells, " Breast Cancer Research and Treatment, vol. 133, no. 2, pp. 635-648, 2012.
64. K. Glunde, C. Jie, and Z. M. Bhujwalla, "Molecular causes of the aberrant choline phospholipid metabolism in breast cancer, " Cancer Research, vol. 64, no. 12, pp. 4270-4276, 2004.
65. E. Ackerstaff, B. R. Pflug, J. B. Nelson, and Z. M. Bhujwalla, "Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells, " Cancer Research, vol. 61, no. 9, pp. 3599-3603, 2001.
66. S. Herminghaus, U. Pilatus, W. Mller-Hartmann et al. , "Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors, " NMR in Biomedicine, vol. 15, no. 6, pp. 385-392, 2002.
67. S. Ishikawa, I. Tateya, T. Hayasaka et al. , "Increased expression of phosphatidylcholine (16:0/18:1) and (16:0/18:2) in thyroid papillary cancer, " PLoS ONE, vol. 7, no. 11, Article ID e48873, 2012.
68. A. C. Kuesel, S. M. Donnelly, W. Halliday, G. R. Sutherland, and I. C. P. Smith, "Mobile lipids and metabolic heterogeneity of brain tumours as detectable by ex vivo 1H MR spectroscopy, " NMR in Biomedicine, vol. 7, no. 4, pp. 172-180, 1994.
69. A. Z. Fernandis and M. R. Wenk, "Lipid-based biomarkers for cancer, " Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 877, no. 26, pp. 2830-2835, 2009.
70. K. Jelonek, M. Ros, M. Pietrowska, and P. Widlak, "Cancer biomarkers andmass spectrometry-based analyses of phospholipids in body fluids, " Clinical Lipidology, vol. 8, no. 1, pp. 137-150, 2013.
71. D. M. Brizel, T. Schroeder, R. L. Scher et al. , "Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer, " International Journal of Radiation Oncology, Biology, Physics, vol. 51, no. 2, pp. 349-353, 2001.
72. S. Walenta, T. Schroeder, and W. Mueller-Klieser, "Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology, " Current Medicinal Chemistry, vol. 11, no. 16, pp. 2195-2204, 2004.
73. M.-B. Tessem, M. G. Swanson, K. R. Keshari et al. , "Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues, " Magnetic Resonance in Medicine, vol. 60, no. 3, pp. 510-516, 2008.
74. I. S. Gribbestad, B. Sitter, S. Lundgren, J. Krane, andD. Axelson, "Metabolite composition in breast tumors examined by proton nuclearmagnetic resonance spectroscopy, " Anticancer Research, vol. 19, no. 3, pp. 1737-1746, 1999.
75. B. Sitter, S. Lundgren, T. F. Bathen, J. Halgunset, H. E. Fjosne, and I. S. Gribbestad, "Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters, " NMR in Biomedicine, vol. 19, no. 1, pp. 30-40, 2006.
76. L. Bartella, S. B. Thakur, E. A. Morris et al. , "Enhancing nonmass lesions in the breast: evaluation with proton (1H) MR spectroscopy, " Radiology, vol. 245, no. 1, pp. 80-87, 2007.
77. T. F. Bathen, L. R. Jensen, B. Sitter et al. , "MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status, " Breast Cancer Research and Treatment, vol. 104, no. 2, pp. 181-189, 2007.
78. C. L. Florian, N. E. Preece, K. K. Bhakoo, S. R. Williams, and M. D. Noble, "Cell type-specific fingerprinting of meningioma and meningeal cells by proton nuclear magnetic resonance spectroscopy, " Cancer Research, vol. 55, no. 2, pp. 420-427, 1995.
79. R. J. Maxwell, I. Martez-Prez, S. Cerdn et al. , "Pattern recognition analysis of 1H NMR spectra from perchloric acid extracts of human brain tumor biopsies, " Magnetic Resonance in Medicine, vol. 39, no. 6, pp. 869-877, 1998.
80. C. Dowling, A. W. Bollen, S. M. Noworolski et al. , "Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens, "American Journal of Neuroradiology, vol. 22, no. 4, pp. 604-612, 2001.
81. L. L. Cheng, C.-L. Wu, M. R. Smith, and R. G. Gonzalez, "Nondestructive quantitation of spermine in human prostate tissue samples using HRMAS 1H NMR spectroscopy at 9. 4 T, " FEBS Letters, vol. 494, no. 1-2, pp. 112-116, 2001.
82. W. B. Dunn, N. J. C. Bailey, and H. E. Johnson, "Measuring the metabolome: current analytical technologies, " Analyst, vol. 130, no. 5, pp. 606-625, 2005.
83. O. Fiehn, D. Robertson, J. Griffin et al. , "The metabolomics standards initiative (MSI), " Metabolomics, vol. 3, no. 3, pp. 175-178, 2007.
84. J. L. Griffin, A. W. Nicholls, C. A. Daykin et al. , "Standard reporting requirements for biological samples in metabolomics experiments: Mammalian/in vivo experiments, " Metabolomics, vol. 3, no. 3, pp. 179-188, 2007.
85. L. W. Sumner, A. Amberg, D. Barrett et al. , "Proposed minimum reporting standards for chemical analysis, " Metabolomics, vol. 3, no. 3, pp. 211-221, 2007.
86. D. V. Rubtsov, H. Jenkins, C. Ludwig et al. , "Proposed reporting requirements for the description of NMR-based metabolomics experiments, " Metabolomics, vol. 3, no. 3, pp. 223-229, 2007.
87. R. Goodacre, D. Broadhurst, A. K. Smilde et al. , "Proposed minimum reporting standards for data analysis in metabolomics, " Metabolomics, vol. 3, no. 3, pp. 231-241, 2007.
88. H. Wu, R. Xue, Z. Tang et al. , "Metabolomic investigation of gastric cancer tissue using gas chromatography/mass spectrometry, " Analytical and Bioanalytical Chemistry, vol. 396, no. 4, pp. 1385-1395, 2010.
89. E. H. Seeley and R. M. Caprioli, "MALDI imaging mass spectrometry of human tissue: method challenges and clinical perspectives, " Trends in Biotechnology, vol. 29, no. 3, pp. 136-143, 2011.
90. C. M. Rocha, A. S. Barros, A. M. Gil et al. , "Metabolic profiling of human lung cancer tissue by 1H high resolution magic angle spinning (HRMAS) NMR spectroscopy, " Journal of Proteome Research, vol. 9, no. 1, pp. 319-332, 2010.
91. H. Wu, A. D. Southam, A. Hines, and M. R. Viant, "Highthroughput tissue extraction protocol forNMR-andMS-based metabolomics, " Analytical Biochemistry, vol. 372, no. 2, pp. 204-212, 2008.
92. L. Cheng, S. Zhang, G. T. MacLennan et al. , "Laser-assisted microdissection in translational research: theory, technical considerations, and future applications, " Applied Immunohistochemistry and Molecular Morphology, vol. 21, no. 1, pp. 31-47, 2013.
93. A. D. Kelly, S. B. Breitkopf, M. Yuan, J. Goldsmith, D. Spentzos, and J. M. Asara, "Metabolomic profiling from formalin-fixed, paraffin-embedded tumor tissue using targeted LC/MS/MS: application in sarcoma, " PLoS ONE, vol. 6, no. 10, Article ID e25357, 2011.
94. K. Dettmer, P. A. Aronov, and B. D. Hammock, "Mass spectrometry-based metabolomics, " Mass Spectrometry Reviews, vol. 26, no. 1, pp. 51-78, 2007.
95. A. Jiye, J. Trygg, J. Gullberg et al. , "Extraction and GC/MS analysis of the human blood plasma metabolome, " Analytical Chemistry, vol. 77, no. 24, pp. 8086-8094, 2005.
96. N. J. Serkova, J. L. Spratlin, and S. G. Eckhardt, "NMRbasedmetabolomics: translational application and treatment of cancer, " Current Opinion inMolecularTherapeutics, vol. 9, no. 6, pp. 572-585, 2007.
97. S. G. Villas-Boâs, S. Mas, M. Akesson, J. Smedsgaard, and J. Nielsen, "Mass spectrometry in metabolome analysis, " Mass Spectrometry Reviews, vol. 24, no. 5, pp. 613-646, 2005.
98. M. Stobiecki, "Application of mass spectrometry for identification and structural studies of flavonoid glycosides, " Phytochemistry, vol. 54, no. 3, pp. 237-256, 2000.
99. K. A. Kouremenos, M. Johansson, and P. J. Marriott, "Advances in gas chromatographic methods for the identification of biomarkers in cancer, " Journal of Cancer, vol. 3, no. 1, pp. 404-420, 2012.
100. E. C. Y. Chan, P. K. Koh, M. Mal et al. , "Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS), " Journal of Proteome Research, vol. 8, no. 1, pp. 352-361, 2009.
101. K. Glunde and Z. M. Bhujwalla, "Metabolic tumor imaging usingmagnetic resonance spectroscopy, " Seminars in Oncology, vol. 38, no. 1, pp. 26-41, 2011.
102. C. B. Lietz, E. Gemperline, and L. Li, "Qualitative and quantitative mass spectrometry imaging of drugs and metabolites, " Advanced Drug Delivery Reviews, vol. 65, no. 8, pp. 1074-1085, 2013.
103. S. R. Ellis, S. H. Brown, M. I. H. Panhuis, S. J. Blanksby, and T. W. Mitchell, "Surface analysis of lipids by mass spectrometry: more than just imaging, " Progress in Lipid Research, vol. 52, no. 4, pp. 329-353, 2013.
104. N. Sun and A. Walch, "Qualitative and quantitative mass spectrometry imaging of drugs and metabolites in tissue at therapeutic levels, " Histochemistry and Cell Biology, vol. 140, no. 2, pp. 93-104, 2013.
105. M. Katajamaa and M. Oresic, "Data processing for mass spectrometry-basedmetabolomics, " Journal of Chromatography A, vol. 1158, no. 1-2, pp. 318-328, 2007.
106. J. J. Ellinger, R. A. Chylla, E. L. Ulrich, and J. L. Markley, "Databases and software for NMR-based metabolomics, " Current Metabolomics, vol. 1, no. 1, pp. 28-40, 2013.
107. D. S. Wishart, D. Tzur, C. Knox et al. , "HMDB:The Human Metabolome Database, " Nucleic Acids Research, vol. 35, no. 1, pp. D521-D526, 2007.
108. C. A. Smith, G. O'Maille, E. J. Want et al. , "METLIN:Ametabolite mass spectral database, " Therapeutic Drug Monitoring, vol. 27, no. 6, pp. 747-751, 2005.
109. J. Kopka, N. Schauer, S. Krueger et al. , "GMD@CSB. DB: The Golm Metabolome Database, " Bioinformatics, vol. 21, no. 8, pp. 1635-1638, 2005.
110. H. Horai, M. Arita, S. Kanaya et al. , "MassBank: a public repository for sharing mass spectral data for life sciences, " Journal of Mass Spectrometry, vol. 45, no. 7, pp. 703-714, 2010.
111. E. Fahy, M. Sud, D. Cotter, and S. Subramaniam, "LIPIDMAPS online tools for lipid research, " Nucleic Acids Research, vol. 35, no. 2, pp. W606-W612, 2007.
112. J. C. Lindon, E. Holmes, and J. K. Nicholson, "Pattern recognition methods and applications in biomedical magnetic resonance, " Progress in Nuclear Magnetic Resonance Spectroscopy, vol. 39, no. 1, pp. 1-40, 2001.
113. R. Madsen, T. Lundstedt, and J. Trygg, "Chemometrics in metabolomics-a review in human disease diagnosis, " Analytica Chimica Acta, vol. 659, no. 1-2, pp. 23-33, 2010.
114. G. Blekherman, R. Laubenbacher, D. F. Cortes et al. , "Bioinformatics tools for cancer metabolomics, " Metabolomics, vol. 7, no. 3, pp. 329-343, 2011.
115. A. Carpi, J. I. Mechanick, S. Saussez, and A. Nicolini, "Thyroid tumormarker genomics and proteomics: diagnostic and clinical implications, " Journal of Cellular Physiology, vol. 224, no. 3, pp. 612-619, 2010.
116. S. Deja, T. Dawiskiba, W. Balcerzak et al. , "Follicular adenomas exhibit a unique metabolic profile. 1H NMR studies of thyroid lesions, " PLoS ONE, vol. 8, no. 12, Article IDe84637, 2013.
117. L. Torregrossa, L. Shintu, J. Nambiath Chandran et al. , "Toward the reliable diagnosis of indeterminate thyroid lesions: a HRMAS NMR-based metabolomics case of study, " Journal of Proteome Research, vol. 11, no. 6, pp. 3317-3325, 2012.
118. Z. Yao, P. Yin, D. Su et al. , "Serum metabolic profiling and features of papillary thyroid carcinoma and nodular goiter, " Molecular BioSystems, vol. 7, no. 9, pp. 2608-2614, 2011.
119. P. Russell, C. L. Lean, L. Delbridge, G. L. May, S. Dowd, and C. E. Mountford, "Proton magnetic resonance and human thyroid neoplasia I: discrimination between benign and malignant neoplasms, " The American Journal of Medicine, vol. 96, no. 4, pp. 383-388, 1994.
120. L. Delbridge, C. L. Lean, P. Russell et al. , "Proton magnetic resonance and human thyroid neoplasia II: potential avoidance of surgery for benign follicular neoplasms, " World Journal of Surgery, vol. 18, no. 4, pp. 512-516, 1994.
121. C. L. Lean, L. Delbridge, P. Russell et al. , "Diagnosis of follicular thyroid lesions by proton magnetic resonance on fine needle biopsy, "The Journal of Clinical Endocrinology&Metabolism, vol. 80, no. 4, pp. 1306-1311, 1995.
122. W. B. Mackinnon, L. Delbridge, P. Russell et al. , "Twodimensional proton magnetic resonance spectroscopy for tissue characterization of thyroid neoplasms, " World Journal of Surgery, vol. 20, no. 7, pp. 841-847, 1996.
123. K. Raffelt, D. Moka, F. Sllentrop, M. Dietlein, J. Hahn, and H. Schicha, "Systemic alterations in phospholipid concentrations of blood plasma in patients with thyroid carcinoma: an invitro 31P high-resolution NMR study, " NMR in Biomedicine, vol. 13, no. 1, pp. 8-13, 2000.
124. Y. Yoshioka, J. Sasaki, M. Yamamoto, K. Saitoh, S. Nakaya, and M. Kubokawa, "Quantitation by 1H-NMR of dolichol, cholesterol and choline-containing lipids in extracts of normal and phathological thyroid tissue, " NMR in Biomedicine, vol. 13, no. 7, pp. 377-383, 2000.
125. K. W. Jordan, C. B. Adkins, L. L. Cheng, and W. C. Faquin, "Application of magnetic-resonance-spectroscopy-based metabolomics to the fine-needle aspiration diagnosis of papillary thyroid carcinoma, " Acta Cytologica, vol. 55, no. 6, pp. 584-589, 2011.
126. R. Elshafey, A. Elattar, M. Mlees, and N. Esheba, "Role of quantitative diffusion-weighted MRI and 1H MR spectroscopy in distinguishing between benign and malignant thyroid nodules, " The Egyptian Journal of Radiology and NuclearMedicine, vol. 45, no. 1, pp. 89-96, 2014.
127. Y. Guo, X. Wang, L. Qiu et al. , "Probing gender-specific lipid metabolites and diagnostic biomarkers for lung cancer using Fourier transformion cyclotron resonancemass spectrometry, " Clinica Chimica Acta, vol. 414, pp. 135-141, 2012.
128. F. Li, X. Qin, H. Chen et al. , "Lipid profiling for early diagnosis and progression of colorectal cancer using direct-infusion electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry, " Rapid Communications in Mass Spectrometry, vol. 27, no. 1, pp. 24-34, 2013.
129. A. D. King, D. K. W. Yeung, A. T. Ahuja et al. , "In vivo 1H MR spectroscopy of thyroid carcinoma, " European Journal of Radiology, vol. 54, no. 1, pp. 112-117, 2005.
130. N. Gupta, A. K. Kakar, V. Chowdhury, P. Gulati, L. R. Shankar, and A. Vindal, "Magnetic resonance spectroscopy as a diagnostic modality for carcinoma thyroid, " European Journal of Radiology, vol. 64, no. 3, pp. 414-418, 2007.
131. Y. Ide, M. Waki, T. Hayasaka et al. , "Human Breast cancer tissues contain abundant phosphatidylcholine(36:1)with high stearoyl-CoA desaturase-1 expression, " PLoS ONE, vol. 8, no. 4, Article ID e61204, 2013.
132. C. A. vonRoemeling, L. A. Marlow, J. J. Wei et al. , "Stearoyl-CoA desaturase 1 is a novelmolecular therapeutic target for clear cell renal cell carcinoma, " Clinical Cancer Research, vol. 19, no. 9, pp. 2368-2380, 2013.
133. M. K. Gupta, D. B. Singh, S. K. Rath, and K. Misra, "Metabolic modeling and simulation analysis of thyroid disorder pathway, " Journal of Computer Science & Systems Biology, vol. 5, no. 2, pp. 52-61, 2012.
134. M. K. Gupta, D. B. Singh, R. Shukla, and K. Misra, "A comprehensive metabolic modeling of thyroid pathway in relation to thyroid pathophysiology and therapeutics, " OMICS: A Journal of Integrative Biology, vol. 17, no. 11, pp. 584-593, 2013.